Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
暂无分享,去创建一个
S. Ostrand-Rosenberg | N. Patterson | S. Baskar | S Ostrand-Rosenberg | S Baskar | N Patterson | V K Clements | V. Clements
[1] C. Benoist,et al. Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Linsley,et al. Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations , 1992, The Journal of experimental medicine.
[3] L. Glimcher,et al. A functional role for signal transduction via the cytoplasmic domains of MHC class II proteins. , 1989, Journal of immunology.
[4] G. Freeman,et al. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression , 1992, Nature.
[5] J. Allison,et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.
[6] R. Schwartz,et al. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.
[7] K. Ozato,et al. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. , 1980, Journal of immunology.
[8] S. Ostrand-Rosenberg,et al. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. , 1991, Journal of immunology.
[9] G. Freeman,et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[10] P. Greenberg,et al. The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. , 1990, Science.
[11] J. Johnston,et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.
[12] P. Linsley,et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.
[13] P. Greenberg. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.
[14] P. Stern,et al. Natural history of HLA expression during tumour development. , 1993, Immunology today.
[15] S. Swain. T Cell Subsets and the Recognition of MHC Class , 1983, Immunological reviews.
[16] L. Glimcher,et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice , 1995, The Journal of experimental medicine.
[17] S. Ostrand-Rosenberg,et al. Rejection of mouse sarcoma cells after transfection of MHC class II genes. , 1990, Journal of immunology.
[18] P. Linsley,et al. The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.
[19] L. Glimcher,et al. Antigen presentation abrogated in cells expressing truncated Ia molecules. , 1989, Journal of immunology.
[20] C. Janeway,et al. Monoclonal antibodies specific for Ia glycoproteins raised by immunization with activated T cells: possible role of T cellbound Ia antigens as targets of immunoregulatory T cells. , 1984, Journal of immunology.
[21] P. Greenberg,et al. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. , 1986, Journal of immunology.
[22] I. Hart. The selection and characterization of an invasive variant of the B16 melanoma. , 1979, The American journal of pathology.
[23] B. Vogelstein,et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.
[24] J. Buerstedde,et al. The assignment of chain specificities for anti-Ia monoclonal antibodies using L cell transfectants. , 1986, Journal of immunology.
[25] H. Ananthaswamy,et al. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. , 1993, Journal of immunology.
[26] M. Kripke,et al. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. , 1979, Journal of the National Cancer Institute.
[27] G. Powers,et al. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. , 1994, Journal of immunology.